Drug Trial Radar · NCT07780929
A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3
Planned (sponsor's estimate)
Start
Nov 17, 2025
Primary completion
Aug 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriasis is a chronic, recurrent, inflammatory, and systemic disease mediated by immunity, induced by a combination of genetic and environmental factors. Its typical clinical manifestations are scaly erythema or plaques, which may be localized or widespread. It is non-contagious, difficult to treat, and often lifelong. The etiology of psoriasis involves multiple factors, including genetics, immunity, and environment. Through an immune response primarily mediated by T lymphocytes and jointly participated in by various immune cells, it causes hyperproliferation of keratinocytes or inflammation in joint synovial cells and chondrocytes. Psoriasis is an incurable disease; however, numerous therapeutic drugs and methods are currently available. Treatment regimens should be determined based on patient symptoms: mild psoriasis is mainly treated with topical therapies, while moderate-to-severe cases can be managed with systemic therapies. Targeted biologics may be appropriately selected for patients who show an inadequate response to traditional systemic therapies. The goals of psoriasis treatment focus on controlling symptoms and improving patients' quality of life. Psoriasis is classified into different subtypes, among which plaque psoriasis is the most common subtype (accounting for approximately 90%). Among these, about 80% of psoriasis patients have mild disease, with topical drug therapy being the preferred first-line treatment. Currently, commonly used topical agents include vitamin D3 derivatives, glucocorticoids, retinoids, and topical combination preparations. Recent studies have revealed that the interaction between lipocalin-2 (LCN2) and its receptor SLC22A17 plays a key role in the pathogenesis and progression of psoriasis: the LCN2/SLC22A17 axis induces abnormal cholesterol metabolism in keratinocytes by activating the SREBP2 pathway, and acts synergistically with the NLRC4 inflammasome to trigger the release of inflammatory mediators such as IL-1$\\beta$ and IL-18. This chemoselectively recruits and activates neutrophils, establishing a continuously amplified inflammatory cascade. Notably, direct inhibitors or antagonists targeting the SLC22A17 receptor have not been fully developed in existing technologies, and reports regarding the molecular structures, selectivity, and druggability of relevant compounds remain rare. Most studies are still confined to preliminary exploration via genetic intervention or antibody blockade, lacking molecular entities that can be translated into clinical applications. By screening and validating the potential of the specific small-molecule compound XJH05 to achieve upstream intervention in psoriasis by targeting SLC22A17, we aim to provide a therapeutic solution for psoriasis that possesses both mechanistic innovation and clinical feasibility. This small-molecule drug can specifically bind to the active site of the SLC22A17 protein, blocking the interaction between SLC22A17 and LCN2. Consequently, it inhibits the activation of the LCN2-SREBP2-NLRC4 signaling axis and downregulates the expression of pro-inflammatory cytokines, thereby blocking at the molecular level both the pathological hyperproliferation of epidermal keratinocytes and the infiltration of immune cells such as neutrophils, which are characteristic features of psoriasis. Although numerous drugs and therapeutic methods are currently available for psoriasis, it remains an incurable disease. Through animal experiments and in vitro drug interventions on psoriasis patient skin lesions, we have demonstrated that the small-molecule drug XJH05 is safe, effective, and free of adverse reactions; however, clinical data regarding XJH05 ointment in the treatment of patients with plaque psoriasis are still lacking. Therefore, we plan to conduct a prospective, interventional, exploratory study on the efficacy of XJH05 ointment in treating plaque psoriasis, hoping to provide further evidence regarding the therapeutic efficacy of XJH05 ointment in the psoriasis patient population.
Conditions
- Psoriasis
- Psoriasis (PsO)
Interventions
XJH05 ointmentDrug
Apply the small molecule compound XJH05 ointment twice daily and apply it for 4 weeks. Evenly apply the ointment on the affected area and massage it. Use the standard amount of approximately 500mg per fingertip, which covers about two palm areas. Take skin mirror photos of the patient's affected area at 0 and 4 weeks after enrollment for record. After 4 weeks of treatment, evaluate the improvement of the patient's PGA score and the itch NRS score.
Calcipotriol ointmentDrug
Apply the calcipotriol ointment twice daily and apply it for 4 weeks. Evenly apply the ointment on the affected area and massage it. Use the standard amount of approximately 500mg per fingertip, which covers about two palm areas. Take skin mirror photos of the patient's affected area at 0 and 4 weeks after enrollment for record. After 4 weeks of treatment, evaluate the improvement of the patient's PGA score and the itch NRS score.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observation of the changes in the phenotypes of psoriasis lesions before and after treatment using dermoscopyTime frame: From enrollment to the end of treatment at 4 weeks
- PGA scoreTime frame: From enrollment to the end of treatment at 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Dermatology, Xijing Hospital, Air Force Medical University
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.